Electric Field Therapy: Results of the Phase 3 Trial (Novocure EF-14): A New Standard for the Treatment of Glioblastoma?

Electric Field Therapy: Results of the Phase 3 Trial (Novocure EF-14): A New Standard for the Treatment of Glioblastoma?

In this brief presentation, neurosurgeon Steven Brem, MD, reviews Novo-TTF (tumor-treating fields), a modality for glioblastoma that involves the induction of a low intensity electric field within the brain to disrupt cell division during mitosis. Dr. Brem reports on the key study findings, and the known advantages of TTF, which include a significant prolongation of progression-free and overall survival, improved quality of life, absence of cognitive decline and seizures, and few side effects.

 

 

Related Links


Published

September 20, 2016

Created by

Penn Physician VideoLink